International Journal of Advanced Research in Science, Engineering and Technology

ISSN: 2350-0328

IJARSET IMPACT FACTOR 7.150

Vol. 12, Issue 12, December 2025

A Review on Artificial Intelligence in Formulation Development and Drug Delivery Systems

K.Malleswari Dr.D.Rama Brahma Reddy J.Tejaswini

Department of pharmaceutics,Nalanda institute of pharmaceutical sciences,Siddharth Nagar, Kantepudi(V), Sattenapalli(M),Guntur(DIST)-522438,AP,India
Department of phytochemistry, Nalanda institute of pharmaceutical sciences,Siddarth Nagar, Kantepudi(V), Sattenapalli(M), Guntur(DIST)-522438,AP,India
Student of B.Pharmacy, Nalanda institute of pharmaceutical sciences, Siddharth Nagar, Kantepudi (V), Sattenapalli (M),Guntur(DIST)-522438,AP,India

ABSTRACT: Artificial Intelligence (AI) has become a powerful enabler in pharmaceutical formulation development and drug delivery research, offering data-driven solutions that address the limitations of conventional trial-and-error methods. By leveraging machine learning (ML), deep learning (DL), computational modeling, and automation, AI accelerates formulation design, enhances prediction accuracy, and reduces development timelines. ML and DL algorithms efficiently analyze complex datasets to predict key formulation attributes, including solubility, stability, drug–excipient compatibility, dissolution profiles, and in vivo performance. These capabilities support the rapid optimization of tablets, capsules, emulsions, suspensions, and advanced nanotechnology-based systems such as liposomes, polymeric nanoparticles, micelles, and hydrogels.[1]
In the development of controlled and targeted drug delivery systems, AI facilitates the simulation of drug release kinetics, polymer behavior, particle interactions, and biological responses, enabling improved material selection and design precision. AI is also transforming pharmaceutical manufacturing through its integration with Process Analytical Technology (PAT), digital twins, and continuous processing platforms, ensuring real-time quality monitoring, predictive maintenance, and reduced batch variability. In personalized medicine, AI contributes to patient-specific dosage forms, 3D-printed drug products, and smart drug delivery devices capable of automated dose adjustment.
Despite its wide-ranging potential, the adoption of AI faces challenges, including limited high-quality datasets,regulatory uncertainties, model interpretability issues, and the need for improved AI competency within the pharmaceutical workforce.[2]Nevertheless, ongoing advancements in computational tools, digital infrastructure, and regulatory acceptance are expected to overcome these barriers. Overall, AI is poised to revolutionize formulation development and modern drug delivery by improving efficiency, accuracy, and patient-centric outcomes.

KEYWORDS: Artificial Intelligence, Drug Formulation, Drug Delivery Systems, Machine Learning, Predictive Modeling, Personalized Medicine.

I.INTRODUCTION

Pharmaceutical formulation development plays a critical role in transforming active pharmaceutical ingredients (APIs) into safe, stable, and efficacious dosage forms. Traditionally, formulation design has depended heavily on empirical methods, trial-and-error experimentation, and iterative optimization. These approaches, while scientifically valuable, are time-consuming, labor-intensive, and often limited in their ability to handle complex multivariable datasets. In recent years, the increasing complexity of drug molecules, heightened regulatory expectations, demand for personalized medicine, and the need for accelerated development timelines have driven the search for more efficient and predictive formulation strategies.
Artificial Intelligence (AI) has emerged as a transformative technological advancement capable of addressing these challenges by introducing data-driven, automated, and highly accurate predictive tools into pharmaceutical development. AI encompasses a wide spectrum of technologies, including machine learning (ML), deep learning (DL), natural language processing (NLP), computational modeling, and advanced data analytics. These tools

International Journal of Advanced Research in Science, Engineering and Technology

ISSN: 2350-0328

IJARSET IMPACT FACTOR 7.150

Vol. 12, Issue 12, December 2025

enable the identification of patterns, relationships, and trends within large and complex datasets, supporting faster and more reliable decision-making across all stages of formulation and drug delivery research.[3]

In the pharmaceutical domain, AI has demonstrated significant potential in predicting key physicochemical properties of drug molecules, assessing drug–excipient compatibility, optimizing formulation composition, modeling dissolution and release kinetics, and forecasting stability under various conditions. AI-based algorithms can simulate formulation performance even before laboratory trials begin, thereby reducing experimental workload, minimizing material usage, and shortening development time. Moreover, AI has facilitated the development of advanced drug delivery systems, including nanoparticles, liposomes, micelles, hydrogels, and implantable devices by predicting their structural, functional, and release characteristics with greater precision.

Beyond formulation design, AI is reshaping pharmaceutical manufacturing through its integration with Process Analytical Technology (PAT), real-time monitoring tools, digital twins, and automated control systems. These advancements support continuous manufacturing, improve process robustness, and enhance overall product quality. Additionally, the emergence of personalized drug delivery systems—such as 3D-printed dosage forms and smart medical devices—has further highlighted AI's role in patient-centric medicine.

Despite its remarkable benefits, the application of AI in formulation science is still evolving and faces several challenges, including data availability, model interpretability, regulatory acceptance, and the need for specialized expertise. Nevertheless, as computational tools advance and the pharmaceutical industry increasingly embraces digital transformation, AI is poised to revolutionize formulation development and usher in a new era of precision-driven drug delivery systems.

II.ROLE OF AI IN PHARMACEUTICAL RESEARCH

Artificial Intelligence (AI) has become a pivotal tool in pharmaceutical research, revolutionizing drug discovery, formulation development, process optimization, and personalized medicine. By leveraging technologies such as machine learning (ML), deep learning (DL), natural language processing (NLP), and predictive modeling, AI accelerates decision-making, reduces development costs, and improves the efficiency and precision of pharmaceutical research.

1. Drug Discovery and Design

AI accelerates the early stages of drug development by:

- Identifying potential drug targets and predicting drug–target interactions.
- Screening large chemical libraries in silico for lead compounds.
- Predicting ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties to reduce late-stage failures.
- Optimizing lead molecules for potency, selectivity, and safety.

2. Pre-Formulation Research

AI aids in predicting:

- Physicochemical properties such as solubility, stability, pKa, and LogP.
- Drug–excipient compatibility and polymorphic transitions.
- Permeability and bioavailability trends, supporting rational formulation planning.

3. Formulation Development

AI-driven models optimize:

- Composition and concentration of excipients.
- Tablet, capsule, liquid, semi-solid, and nanoparticle-based formulations.
- Drug release kinetics and stability predictions, reducing trial-and-error experiments.

4. Process Development and Manufacturing

Integration of AI with Process Analytical Technology (PAT) and digital twins allows:

- Real-time monitoring of critical parameters.
- Prediction of batch outcomes and process deviations.
- Continuous manufacturing optimization and predictive maintenance.

5. Clinical Research and Personalized Medicine

AI facilitates:

- Patient selection and stratification for clinical trials.
- Prediction of clinical outcomes and adverse events.[4]
- Development of personalized dosage forms and smart delivery systems.

International Journal of Advanced Research in Science, Engineering and Technology

ISSN: 2350-0328

Vol. 12, Issue 12, December 2025

6. Regulatory Support and Safety

AI supports:

- Toxicological prediction and pharmacovigilance.
- Automated literature and data extraction for regulatory submissions.

III. AI IN FORMULATION DEVELOPMENT

Artificial Intelligence (AI) has become a transformative tool in pharmaceutical formulation development, enabling data-driven decision-making, predictive modeling, and process optimization. By integrating AI into formulation research, scientists can reduce experimental trials, optimize excipient selection, and design dosage forms with improved quality and efficacy. AI applications in formulation development span **pre-formulation studies, solid dosage forms, and controlled or modified release systems**.

1. **Pre-Formulation Studies**

Pre-formulation is the first and critical step in formulation development, focusing on understanding the physicochemical properties of the active pharmaceutical ingredient (API) and its interaction with excipients. AI enhances pre-formulation research by predicting:

- **Solubility and dissolution characteristics**
- **Stability and degradation pathways** under various conditions
- **Drug–excipient compatibility**, avoiding unwanted interactions
- **Partition coefficient, pKa, and permeability** to classify drug behavior

Machine learning (ML) algorithms analyze historical experimental data and literature to identify optimal excipients and formulation parameters. This reduces laboratory workload, accelerates decision-making, and improves the likelihood of successful formulation development.

2. **Solid Dosage Form Development**

Solid dosage forms, including tablets and capsules, remain the most common pharmaceutical products. AI aids in optimizing these formulations by:

- **Predicting tablet properties**: hardness, friability, disintegration time
- **Optimizing excipient concentrations**: binders, disintegrants, fillers
- **Modeling manufacturing processes**: granulation, compression, and coating
- **Enhancing quality control**: AI-driven image analysis detects defects and variability

Artificial neural networks (ANN) and support vector machines (SVM) are commonly employed to establish relationships between formulation variables and final product performance, reducing trial-and-error and improving reproducibility.[5]

3. **Controlled and Modified Release Systems**

Controlled and modified release formulations are designed to release drugs at a desired rate or specific site, improving therapeutic efficacy and patient compliance. AI applications include:

- **Predicting drug release kinetics** from hydrogels, matrices, and implants
- **Optimizing polymer composition and degradation rates**
- **Modeling in vitro–in vivo correlations (IVIVC)** for better clinical predictability
- **Designing stimuli-responsive or site-specific delivery systems** using nanocarriers or osmotic pumps

AI enables the simulation of formulation performance, allowing scientists to fine-tune release profiles and ensure consistent therapeutic outcomes.

IV.AI IN ADVANCED DRUG DELIVERY SYSTEMS

Artificial Intelligence (AI) has become a key driver in the design and optimization of **advanced drug delivery systems**, enabling the development of therapies that are more precise, effective, and patient-centric. By leveraging machine learning (ML), deep learning (DL), and predictive modeling, AI helps in understanding complex biological interactions, optimizing formulation parameters, and improving therapeutic outcomes. Key areas where AI impacts advanced drug delivery include **nanotechnology-based systems, targeted delivery, and personalized/smart drug delivery**.

1. Nanotechnology-Based Drug Delivery:

   Nanotechnology-based drug delivery systems, such as nanoparticles, liposomes, micelles, and nanogels, enhance drug solubility, stability, and bioavailability. AI contributes to their development by:

   - **Predicting particle characteristics**: size, polydispersity index (PDI), zeta potential, and morphology

ISSN: 2350-0328

IJARSET IMPACT FACTOR 7.150

- **Optimizing drug loading and encapsulation efficiency**
- **Modeling in vitro and in vivo drug release kinetics**
- **Designing ligand-functionalized nanoparticles** for improved cellular uptake

Machine learning models analyze experimental and simulation data to identify optimal nanoparticle composition and fabrication conditions, reducing the need for extensive laboratory trials.

2. **Targeted Drug Delivery:**

Targeted drug delivery aims to release therapeutic agents specifically at diseased tissues, minimizing systemic side effects. AI enhances this by:

- **Predicting optimal targeting ligands and carriers** for specific receptors or tissues
- **Modeling drug distribution and pharmacokinetics** in different organs
- **Designing controlled-release profiles** for site-specific action[6]
- **Optimizing carrier composition** to enhance bioavailability and reduce toxicity

AI-driven simulations allow precise formulation adjustments to maximize therapeutic efficacy while minimizing adverse effects.

3. Personalized and Smart Drug Delivery:

Personalized and smart drug delivery systems are designed to meet individual patient needs and adapt to real-time physiological conditions. AI facilitates:

- **Development of patient-specific dosage forms**, including 3D-printed tablets and capsules
- **Integration with wearable sensors and IoT devices** for real-time monitoring
- **Automated dose adjustment** based on pharmacokinetic or physiological feedback
- **Adaptive drug release systems** responsive to pH, temperature, or enzyme activity

These AI-enabled systems improve treatment outcomes, patient compliance, and overall healthcare efficiency.

V.AI IN BIOLOGICS AND NOVEL THERAPEUTICS

Biologics, including monoclonal antibodies, vaccines, recombinant proteins, gene therapies, and cell-based therapies, represent a rapidly growing segment of modern medicine. These molecules are often complex, sensitive, and challenging to formulate and deliver. Novel therapeutics, such as RNA-based drugs, gene-editing systems, and peptide therapeutics, also pose unique formulation and delivery challenges. Artificial Intelligence (AI) has emerged as a transformative tool to overcome these challenges by accelerating design, optimizing production, and predicting therapeutic performance.

1. AI in Biologics Development:

AI contributes to biologics development through:

- **Protein structure prediction**: Deep learning models, such as AlphaFold, can predict protein folding and 3D structures, aiding rational design of therapeutic proteins and antibodies.
- **Antibody optimization**: AI algorithms help identify high-affinity antibody sequences, improve stability, and reduce immunogenicity.
- **Vaccine design**: AI assists in epitope mapping, immunogenicity prediction, and multi-epitope vaccine formulation.

Bioprocess optimization: Machine learning predicts optimal cell culture conditions, fermentation parameters, and yield

Novel therapeutics, including gene therapies, mRNA vaccines, and peptide drugs, benefit from AI in:

- **Sequence optimization**: AI predicts codon usage, secondary structures, and stability of mRNA or gene sequences for enhanced expression.
- **Delivery system design**: AI aids in selecting lipid nanoparticles, viral vectors, or polymeric carriers for efficient cellular uptake and target specificity.
- **Safety and efficacy prediction**: AI models evaluate off-target effects, immunogenicity, and pharmacokinetics of gene or cell-based therapies.
- **Formulation stability**: AI predicts aggregation, degradation, and storage conditions for sensitive biologics and novel therapeutics.

3. Personalized Biologics and Therapies:

AI supports patient-specific biologics and therapies by:

- **Predicting patient response** based on genetic, proteomic, or immunologic profiles.
- **Designing individualized gene therapies** targeting specific mutations.

International Journal of Advanced Research in Science, Engineering and Technology

ISSN: 2350-0328

IJARSET IMPACT FACTOR 7.150

Vol. 12, Issue 12, December 2025

- **Integrating wearable and diagnostic data** for adaptive dosing and therapy monitoring.

VI.AI IN QUALITY BY DESIGN (QbD) AND MANUFACTURING

Quality by Design (QbD) is a systematic approach to pharmaceutical development that emphasizes designing processes and formulations to ensure predefined product quality. Traditional QbD implementation relies on experimental trials, statistical analysis, and empirical adjustments. Artificial Intelligence (AI) enhances QbD and pharmaceutical manufacturing by enabling predictive modeling, process optimization, and real-time quality monitoring, ultimately improving efficiency, consistency, and regulatory compliance.

1.AI in Process Optimization

AI contributes significantly to the optimization of pharmaceutical manufacturing processes:

- **Predictive modeling of process parameters**: Machine learning (ML) algorithms analyze historical process data to predict outcomes such as yield, particle size, or dissolution rates.
- **Digital twins**: Virtual replicas of manufacturing processes simulate process behavior, allowing optimization without extensive laboratory experimentation.
- **Continuous manufacturing**: AI supports real-time monitoring and control of critical process parameters, improving efficiency and reducing batch-to-batch variability.
- **Fault detection and predictive maintenance**: AI identifies potential process deviations or equipment failures before they impact product quality, minimizing downtime and reducing production costs.[7]

By integrating AI with Process Analytical Technology (PAT), manufacturers can maintain consistent process performance while adapting to real-time variability.

2. AI in Quality Control

AI transforms pharmaceutical quality control (QC) through advanced analytics and automation:

- **Real-time product monitoring**: AI algorithms process data from spectroscopy, imaging, and sensors to detect defects or deviations in tablets, capsules, or liquids.
- **Predictive quality assessment**: ML models predict stability, dissolution profiles, and shelf-life based on formulation and process parameters.
- **Automated inspection and classification**: AI-based computer vision systems can identify tablet cracks, coating defects, or particle size inconsistencies faster and more accurately than manual inspection.
- **Regulatory compliance support**: AI assists in analyzing large QC datasets and documenting evidence for regulatory submissions under QbD frameworks.[8]

AI Applications in Pharmacokinetics

1. Absorption Prediction
   AI models accurately predict oral absorption by integrating solubility, permeability, excipient interactions, dissolution data, and gastrointestinal physiology. Deep neural networks and random forest models have shown superior performance in forecasting human fraction absorbed (F_abs), C_max, and Tmax compared to classical regression.
2. Distribution Modeling
   Machine learning enhances prediction of tissue partitioning, plasma protein binding, and volume of distribution (Vd). Graph neural networks (GNNs) can learn molecular features affecting membrane permeability and tissue affinity, improving PBPK tissue model calibration.
3. Metabolism and Enzyme Interaction Prediction
   AI models identify metabolic pathways, CYP450 interactions, and metabolite profiles using molecular fingerprints and structural descriptors. Classification algorithms can flag CYP inhibitors and inducers early, reducing toxicity risks.
4. Clearance and Elimination
   Ensemble models predict renal and hepatic clearance by integrating physicochemical properties, in vitro data, transporter interactions, and plasma protein binding. These models help refine PBPK model parameters and support early dose optimization.
5. Physiologically-Based Pharmacokinetic (PBPK) Model Enhancement
   AI augments PBPK modeling by:
   - Optimizing input parameters through ML-based estimation.
   - Handling sparse or noisy datasets using deep learning imputation.[9]

International Journal of Advanced Research in Science, Engineering and Technology

ISSN: 2350-0328

IJARSET IMPACT FACTOR 7.150

Vol. 12, Issue 12, December 2025

- Providing surrogate models that replace computationally expensive simulations.

AI for Drug Performance Prediction

1. Bioavailability Forecasting

Machine learning predicts oral bioavailability based on molecular descriptors, formulation attributes, and PK parameters. Models estimate absolute bioavailability, food effects, and formulation-dependent variability.[10]

2. Exposure–Response and Efficacy Prediction

AI models link PK profiles (AUC, C_max, C_min) with pharmacodynamic (PD) responses and clinical endpoints. Deep learning models trained on patient data can forecast therapeutic success and treatment outcomes, supporting personalized therapy.

3. Toxicity and Safety Assessment

AI predicts off-target effects, dose-dependent toxicity, and drug–drug interactions (DDIs). Combining PK with toxicity datasets improves prediction of exposure thresholds associated with adverse events.

4. Population Variability and Personalized Medicine

AI incorporates patient-specific features such as genetics, liver/kidney function, age, disease state, and co-medications. Population-based ML models predict individualized PK profiles for personalized dosing.

5. Drug Release and Performance Modeling[11]

Integrating formulation composition, process parameters, and PK data enables prediction of drug release kinetics and in vivo performance. AI helps bridge in vitro–in vivo correlations (IVIVC), improving regulatory acceptance and formulation design.

VII.CHALLENGES AND LIMITATIONS

AI offers major advantages in formulation development, but several limitations restrict its full implementation.

1. **Complexity of Drug Properties**
   - Many drugs have poor solubility, permeability, or stability.
   - Difficult physicochemical properties complicate formulation design.
2. **Limited Biopharmaceutical Performance**
   - Low bioavailability of many APIs requires complex delivery approaches.
   - Predicting in vivo performance from in vitro studies remains difficult.
3. **Excipient Variability**
   - Differences in excipient grade, source, and batch consistency affect formulation behavior.
   - Lack of excipient compatibility can lead to degradation or instability.
4. **Stability Challenges**
   - Chemical, physical, and microbiological instability can shorten shelf life.
   - Sensitive molecules (biologics, peptides, mRNA) require specialized approaches.
5. **Manufacturing Difficulties**
   - Scale-up from lab to production often introduces variability.[12]
   - Complex processes (granulation, coating, nanoformulation) require precise control.
6. **Regulatory Requirements**
   - Strict quality, safety, and efficacy standards extend development timelines.
   - Extensive documentation and validation are needed for approval.
7. **High Development Costs**
   - Formulation R&D, analytical testing, stability studies, and clinical trials are expensive.
   - Advanced delivery systems (nanocarriers, implants) significantly increase costs.
8. **Time-Consuming Development Process**
   - Trial-and-error experiments prolong optimization.
   - Predicting long-term stability and release profiles takes months to years.
9. **Challenges in Targeted Delivery**
   - Achieving precise targeting to tissues or cells is difficult.
   - Biological barriers (enzymes, pH, immune response) limit efficiency.
10. **Patient Variability**
    - Differences in age, genetics, metabolism, and disease state affect drug response.
    - Formulations must meet diverse patient needs (pediatric, geriatric, chronic diseases).

11. **Limitations of Advanced Drug Delivery Systems**
    - Nanocarriers may face toxicity, aggregation, and clearance issues.
    - Implantable and smart systems may require invasive procedures.
12. **Stability During Storage and Transport**
    - Temperature, humidity, and light can degrade drug products.
    - Cold-chain requirements for biologics add complexity and cost.

VIII.FUTURE PROSPECTIVES

1.**Advancement of Personalized Medicine**
- Formulations tailored to individual patient genetics, metabolism, and disease profiles.
- Personalized dosing and delivery systems designed through AI and pharmacogenomics.

2.**Growth of Smart Drug Delivery Systems**
- Development of stimuli-responsive carriers (pH, temperature, enzymes, magnetic fields).
- Smart implants and wearable drug pumps enabling real-time and controlled dosing.

3.**Expanded Use of Nanotechnology**
- More sophisticated nanocarriers such as nano-liposomes, polymeric nanoparticles, dendrimers, and nanogels.[13]
- Improved targeting, reduced toxicity, and enhanced penetration across biological barriers.

4. **Integration of Artificial Intelligence and Machine Learning**
- Predictive modeling for formulation optimization, stability, and drug release profiles.
- AI-assisted automated laboratories and digital twins for rapid prototyping and simulation.

5.**Advances in Biologics and Novel Therapeutics**
- Improved formulation strategies for peptides, proteins, monoclonal antibodies, mRNA vaccines, gene therapies, and cell-based therapeutics.
- Better stabilization techniques and bioavailability enhancement for large molecules.

6.**Next-Generation Controlled Release Systems**
- More precise, long-acting injectable formulations and biodegradable implants.
- Hybrid systems combining micro/nanotechnology with polymer science for sustained and pulsatile release.

7. **3D Printing in Pharmaceutical Manufacturing**
- Personalized dosage forms with adjustable drug strengths, shapes, and release profiles.
- On-demand printing in hospitals and remote healthcare settings.

8.**Targeted and Site-Specific Drug Delivery[14]**
- Improved ligand–receptor-based targeting for cancer, CNS disorders, and infectious diseases.
- Enhanced methods to cross biological barriers such as the blood–brain barrier and intestinal mucosa.

9.**Regenerative Medicine and Tissue-Engineered Delivery Systems**
- Use of scaffolds, hydrogels, and biomaterials for localized and sustained delivery in tissue repair.[15]
- Combination products integrating drugs with cells or growth factors.

10. Green and Sustainable Formulation Approaches
- Eco-friendly solvents, biodegradable polymers, and energy-efficient manufacturing processes.
- Reduction of hazardous waste and improved environmental sustainability.

IX.CONCLUSION

Formulation development and drug delivery systems continue to evolve rapidly as scientific, technological, and therapeutic needs become more complex. Traditional formulation approaches, although effective, often face limitations related to drug solubility, stability, bioavailability, and patient variability. As new classes of therapeutics—such as biologics, peptides, and nucleic acid–based drugs—emerge, the demand for advanced and more precise delivery systems grows significantly. Recent progress in nanotechnology, material science, and digital tools has greatly strengthened the ability to design targeted, sustained, and patient-centric formulations.

Artificial intelligence, predictive modeling, smart biomaterials, and personalized medicine are expected to play increasingly central roles in addressing current challenges. These innovations not only accelerate development timelines but also improve therapeutic outcomes, enhance patient convenience, and reduce development costs.

Despite facing barriers such as regulatory uncertainties, data limitations, and technical complexities, the field is steadily moving toward more efficient, safe, and adaptable drug delivery solutions.

In summary, the future of formulation development lies in integrating scientific innovation with advanced analytical and digital technologies. Continued research, interdisciplinary collaboration, and supportive regulatory frameworks will be essential to translating these innovations into clinically effective and commercially viable drug products. The combined progress across these areas promises a new era of more effective, personalized, and accessible therapies for global healthcare.

REFERENCES

1) Wang, X. et al. *Artificial intelligence in drug formulation design: opportunities and challenges.* **Advanced Drug Delivery Reviews, 2021,17(1),**150–167.
2) Patel, S. et al. *Machine learning approaches in controlled release and nanomedicine development*. **Journal of Controlled Release,2024, 34(3),** 456–472**.**
3) Zhang, Y. et al. *AI-based predictive modeling in pharmaceutical formulation: a review.* **International Journal of Pharmaceutics, 2021,63(8),** 122–140.
4) Kumar, V. et al. *Integration of AI with Quality by Design in drug development.* **Pharmaceutical Research, 2020,67(4),34-38.**
5) Li, H. et al. *Smart and personalized drug delivery systems guided by artificial intelligence.* **Frontiers in Bioengineering and Biotechnology,2024,24(12),** 10-23.
6) Singh, R. et al. *Artificial intelligence applications in nanotechnology-based drug delivery systems.* **Drug Delivery and Translational Research,2025, 15**(2), 1012–1030.
7) Joshi, S., & Sheth, S. *Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations. Pharmaceutics,2025, 17*(11), 14-40.
8) Singh, A., Nishad, R., & Joshi, K. *A Review Analysis of Drug Delivery System Using Artificial Intelligence.Biomedical Informatics and Smart Healthcare, 2025,1*(2), 52–66.
9) Bharath, E., Thilagavathi, T. S., Jeeva, D., Anbazhagan, S., & Vadivel, S. A. (2025). *Advances in Artificial Intelligence for Drug Discovery and Development: A Review of Current Trends and Applications. Asian Journal of Pharmaceutical Research and Development,2025,13*(2), 67–78.
10) Ali, K. A., Mohin, S., Mondal, P., et al.*Influence of Artificial Intelligence in Modern Pharmaceutical Formulation and Drug Development. Future Journal of Pharmaceutical Sciences,2024,3(4),* 53-56.
11) Parvathaneni, M., Awol, A. K., Kumari, M., Lan, K., & Lingam, M. *Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development. Journal of Drug Delivery and Therapeutics, 2023,13*(1), 151–158.
12) Hrithik Dey, Nisha Arya, Harshita Mathur, Neel Chatterjee & Ruchi Jadon.*Exploring the Role of Artificial Intelligence and Machine Learning in Pharmaceutical Formulation Design. International Journal of Newgen Research in Pharmacy & Healthcare, 2024,2*(1), 30–41.
13) Abhijeet Madhukar Haval, Kumar Shwetabh, & Sushree Sasmita Dash. *Machine Learning-Based Enhanced Drug Delivery System and Its Applications – A Systematic Review. Journal of Angiotherapy, 2024,8(*1), 1–9.
14) Rotake, S. B., Hatwar, P. R., Bakal, R. L., & Meshram, S. I.*The Role of Artificial Intelligence in Drug Discovery. Journal of Drug Delivery and Therapeutics,2025, 15*(7), 102–108.
15) Daniel Xavier Prasad.*Artificial Intelligence's Impact on Contemporary Drug Research and Pharmaceutical Formulation. i-manager Journals*, January–April 2024,25(5),124-135.